Windtree Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Selling, General & Admin	8.24	9.2	10.79	14.47	14.04	Upgrade
Research & Development	16.28	8.14	10.7	17.79	15.37	Upgrade
Operating Expenses	24.52	17.34	21.49	32.26	29.42	Upgrade
Operating Income	-24.52	-17.34	-21.49	-32.26	-29.42	Upgrade
Interest Expense	-0.24	-0.05	-0.05	-0.11	-0.13	Upgrade
Interest & Investment Income	0.07	0.33	0.11	0.09	0.12	Upgrade
Currency Exchange Gain (Loss)	-	-	0.7	-0.3	-1.2	Upgrade
Other Non Operating Income (Expenses)	10.07	0.03	0	-0.02	-1.05	Upgrade
EBT Excluding Unusual Items	-14.61	-17.03	-20.73	-32.6	-31.67	Upgrade
Merger & Restructuring Charges	-0.5	-0.2	-	-	-	Upgrade
Impairment of Goodwill	-	-3.06	-12.62	-	-	Upgrade
Asset Writedown	-1.12	-	-7.22	-45.02	-	Upgrade
Other Unusual Items	14.44	-	-	-	-0.9	Upgrade
Pretax Income	-1.79	-20.29	-40.58	-77.62	-32.57	Upgrade
Income Tax Expense	-0.01	-	-1.37	-9.99	-	Upgrade
Net Income	-1.79	-20.29	-39.21	-67.64	-32.57	Upgrade
Preferred Dividends & Other Adjustments	3.7	-	-	-	-	Upgrade
Net Income to Common	-5.49	-20.29	-39.21	-67.64	-32.57	Upgrade
Shares Outstanding (Basic)	0	-	-	-	-	Upgrade
Shares Outstanding (Diluted)	0	-	-	-	-	Upgrade
EPS (Basic)	-104.35	-	-	-	-	Upgrade
EPS (Diluted)	-104.35	-	-	-	-	Upgrade
Free Cash Flow	-15.41	-13.45	-19.47	-23.94	-25.61	Upgrade
Free Cash Flow Per Share	-293.14	-	-	-	-	Upgrade
EBITDA	-24.44	-17.26	-21.36	-32.07	-29.25	Upgrade
D&A For EBITDA	0.08	0.08	0.13	0.19	0.17	Upgrade
EBIT	-24.52	-17.34	-21.49	-32.26	-29.42	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q